3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
11
Papillomavirus Infections
5
Uterine Cervical Dysplasia
4
Uterine Cervical Diseases
2
Squamous Intraepithelial Lesions
2
Precancerous Conditions
2
Genital Diseases
2
Atypical Squamous Cells of the Cervix
2
Uterine Neoplasms
1
Uterine Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Neoplasms by Site
1
Neoplasms
1
HIV Infections
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Female Urogenital Diseases and Pregnancy Complications
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Colposcopy
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled